Gland Pharma IPO To Open On November 9, Price Fixed At Rs 1,490-1,500 A Share
Gland Pharma IPO (initial public offering) will open for bidding on November 9. The public issue will be open for three days, from November 9 to November 11. The Hyderabad-based company has fixed the public issue in the price band at Rs 1,490-1,500 per share.
Gland Pharma will be the first big Indian company, with Chinese parentage, to go public in the country.
The Gland Pharma public offer will be the largest pharma IPO in the country. It aims to raise Rs 6,479.54 crore through the public issue, at the higher end of the price band. Eris Lifesciences, which raised Rs 1,741 crore in 2017, was the biggest pharma primary issue to hit Dalal Street thus far. Other prominent pharma companies i.e. Alkem Labs and Laurus Labs raised Rs 1,350 crore each in 2015 and 2016 respectively.
The IPO comprises fresh issue of shares amounting to up to Rs 1,250 crore and an offer for sale (OFS) of more than 3.4 crore shares. The OFS includes sale of up to 1.94 crore shares by Fosun Pharma Industrial Pte Ltd, 1 crore shares by Gland Celsus Bio Chemicals Pvt Ltd, 35.73 lakh shares by Empower Discretionary Trust and 18.74 lakh shares by Nilay Discretionary Trust.
Applicants can bid for a minimum one lot of 10 equity shares and in multiples of 10 shares thereafter, up to 13 lots.
The proceeds from the public offer will be used to meet the company's working capital requirements and for general corporate purposes.
Gland Pharma was founded by P V N Raju in the year 1978. The China-based Fosun Pharma holds majority stake of 74 per cent stake in the company.
Gland Pharma manufactures and markets complex injectables. It has seven manufacturing facilities across India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. Gland Pharma sells products in more than 60 countries, including the United States, Europe, Canada, Australia and India.
The primary market offering by Gland Pharma will be the 13th IPO in 2020. SBI Card, Rossari Biotech, Mindspace Business Parks REIT, Route Mobile, Happiest Minds Technologies, Chemcon Speciality Chemicals, Computer Age Management Services, Angel Broking, UTI Asset Management Company and Mazagon Dock Shipbuilders are among the major companies to list during the year.
Kotak Mahindra Capital Company, Citigroup Global Markets India, Haitong Securities India and Nomura Financial Advisory and Securities India are the book running lead managers to the issue.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
